Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population

Autor: Gaston van Hassel, Peter van der Meer, Jelmer J van Zanden, S Heleen Binnenmars, Michele F Eisenga, Martin H. de Borst, Stephan J. L. Bakker, Gerjan Navis, Ilja M. Nolte, Lyanne M. Kieneker, Adriaan A. Voors, Yook Chin Chia
Přispěvatelé: Life Course Epidemiology (LCE), Cardiovascular Centre (CVC), Value, Affordability and Sustainability (VALUE), Groningen Kidney Center (GKC), Groningen Institute for Organ Transplantation (GIOT), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE)
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
Epidemiology
030204 cardiovascular system & hematology
Left ventricular hypertrophy
general population
Ventricular Function
Left
0302 clinical medicine
Risk Factors
030212 general & internal medicine
Prospective Studies
Original Research
Netherlands
RISK
education.field_of_study
Ejection fraction
Incidence
Hazard ratio
Middle Aged
PROINFLAMMATORY CYTOKINES
Population Surveillance
Cardiology
Disease Progression
Female
Cardiology and Cardiovascular Medicine
Cohort study
heart failure with preserved ejection fraction
Adult
medicine.medical_specialty
Population
interleukin 6
03 medical and health sciences
MORBIDITY
LEFT-VENTRICULAR HYPERTROPHY
Internal medicine
medicine
Diseases of the circulatory (Cardiovascular) system
Humans
education
OLDER-ADULTS
Aged
Heart Failure
business.industry
NATRIURETIC PEPTIDE
Interleukin-6
MORTALITY
MICROALBUMINURIA
Stroke Volume
medicine.disease
DYSFUNCTION
Heart failure
RC666-701
Case-Control Studies
ONSET
Microalbuminuria
Heart failure with preserved ejection fraction
business
Biomarkers
Zdroj: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Journal of the American Heart Association, 10(11):018549. Wiley
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 11 (2021)
ISSN: 2047-9980
Popis: Background The cause of heart failure with preserved ejection fraction (HFpEF) is poorly understood, and specific therapies are lacking. Previous studies suggested that inflammation plays a role in the development of HFpEF. Herein, we aimed to investigate in community‐dwelling individuals whether a higher plasma interleukin 6 (IL‐6) level is associated with an increased risk of developing new‐onset heart failure (HF) over time, and specifically HFpEF. Methods and Results We performed a case‐cohort study based on the PREVEND (Prevention of Renal and Vascular End‐Stage Disease) study, a prospective general population‐based cohort study. We included 961 participants, comprising 200 participants who developed HF and a random group of 761 controls. HF with reduced ejection fraction or HFpEF was defined on the basis of the left ventricular ejection fraction of ≤40% or >40%, respectively. In Cox proportional hazard regression analyses, IL‐6 levels were statistically significantly associated with the development of HF (hazard ratio [HR], 1.28; 95% CI, 1.02–1.61; P =0.03) after adjustment for key risk factors. Specifically, IL‐6 levels were significantly associated with the development of HFpEF (HR, 1.59; 95% CI, 1.16–2.19; P =0.004), whereas the association with HF with reduced ejection fraction was nonsignificant (HR, 1.05; 95% CI, 0.75–1.47; P =0.77). In sensitivity analyses, defining HFpEF as left ventricular ejection fraction ≥50%, IL‐6 levels were also significantly associated with the development of HFpEF (HR, 1.47; 95% CI, 1.04–2.06; P =0.03) after adjustment for key risk factors. Conclusions IL‐6 is associated with new‐onset HFpEF in community‐dwelling individuals, independent of potential confounders. Our findings warrant further research to investigate whether IL‐6 might be a novel treatment target to prevent HFpEF.
Databáze: OpenAIRE
Externí odkaz: